<DOC>
	<DOCNO>NCT00354900</DOCNO>
	<brief_summary>There intimate relationship process promote growth , invasion , metastasis cancer , process regulate blood clotting . The enzymes uPA PAI-1 key regulator remodel recently form blood clot , substantial information link great level uPA PAI-1 breast cancer great likelihood breast cancer recurrence death . As uPA PAI-1 excellent marker cancer 's aggressive clinical behavior , uPA PAI-1 may potential target anticancer therapy . Aprotinin inhibitor uPA activation , approve FDA reduce blood loss patient undergoing cardiopulmonary bypass surgery . Studies animal limit study patient show Aprotinin slow growth tumor . Our hypothesis uPA chronically activated malignancy , inhibition uPA Aprotinin would slow rate progression breast cancer .</brief_summary>
	<brief_title>Phase I Study Aprotinin Advanced Breast Cancer</brief_title>
	<detailed_description>Urokinase-type plasminogen activator ( uPA ) serine protease whose physiologic function catalyze conversion plasminogen active proteolytic form , plasmin , participation process require tissue remodel wound healing , embryogenesis inflammatory response . uPA among numerous tissue protease also find association neoplastic disease , play pathologic role tumor growth metastasis . The activity uPA neutralize specific inhibitor , plasminogen activator inhibitor type-1 ( PAI-1 ) form inactive complex 1:1 stoichiometry plasminogen activator . Through inhibition uPA tPA , PAI-1 inhibit plasmin ; inhibitory effect limit extent extracellular matrix protein degradation reduce activation MMP 's angiogenic growth factor VEGF . However , tissue overexpression PAI-1 correlate aggressive clinical behavior malignancy . In fact , upregulation PAI-1 may cellular attempt return homeostasis , disrupt activation uPA factor . Upregulation PAI-1 may indicator uPA pathway contribute aggressive phenotype . Co-expression uPA PAI-1 primary breast tumor tissue associate great risk locoregional distant recurrence , poor response adjuvant hormonal chemotherapy , short survival . Elevation circulate PAI-1 patient metastatic breast cancer associate short survival . We hypothesize uPA activation part responsible clinical progression malignancy . Inhibition uPA therefore rational strategy control advance breast cancer . Aprotinin safe effective protease inhibitor uPA plasmin . Aprotinin approve treatment septic shock , prevention blood loss patient undergoing cardiopulmonary bypass surgery . In patient undergo cardiopulmonary bypass surgery , Aprotinin blunt acute increase fibrinolytic activity cause uPA , decrease expression counter-regulatory PAI-1 . In several vivo tumor model , Aprotinin inhibit tumor growth , invasiveness , metastasis . Limited experience patient cancer suggest prolongation survival patient treat single multiple dos Aprotinin . We hypothesize Aprotinin would delay disease progression decrease chronic activation uPA PAI-1 , delay tumor progression would correlate inhibition laboratory measure fibrinolysis . This Phase I trial . Patients metastatic breast cancer receive escalate dos Aprotinin one four dose cohort , range 2.0 x 106 KIU 6.0 x 106 KIU . Three six patient enter dose cohort , maximum tolerate dose defined high dose few 33 % patient experience dose limit toxicity . A total nine patient enter maximum tolerated dose . The extent disease assess radiologically baseline , 6 , 12 , 18 , 24 week treatment Aprotinin . Coagulation parameter , include PT/PTT , D-Dimer , FDP 's , uPA , PAI-1 assay baseline , several interval 30 day treatment Aprotinin .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Aprotinin</mesh_term>
	<criteria>Patients histologically cytologically proven metastatic breast cancer . Patients least one bidimensionally measurable lesion ( diameter &gt; 1 cm ) , evaluable bone lesion undergo biopsy . Age &gt; 18 year . Life expectancy least 6 month . ECOG performance status 03 . Screening laboratory within follow parameter : ANC &gt; 1500 cells/mm3 , Platelets &gt; 100,000 cells/mm3 , AST &lt; 2 x upper limit normal , Bilirubin &lt; 1.5 x upper limit normal , Calculated creatinine clearance &gt; 30 cc/min Cockroft Gault equation . Concurrent treatment hormonal therapy trastuzumab allow . Patients must postmenopausal ( either result surgery , amenorrhea least 12 consecutive month ) , must practice either abstinence , adequate method contraception ( intrauterine device barrier contraception ) , sexual partner must sterile . Women pregnant , breastfeeding , fertile practice adequate mean contraception exclude . Patients must central venous catheter . Patients must able give informed consent indicate aware investigational nature study . No known CNS metastasis . No treatment cytotoxic chemotherapy allow within 21 day treatment Aprotinin . No treatment investigational agent allow within 21 day treatment Aprotinin . No severe cardiovascular disease include unstable heart rhythm , uncompensated congestive heart failure , unstable angina myocardial infarction within 6 month . No bleed diathesis coagulopathy include concomitant use anticoagulant thromboembolic disease No active anticoagulant therapy ( include antiplatelet agent ) least ten day . No active , uncontrolled bacterial , viral fungal infection . No patient know expected allergic aprotinin , receive prior aprotinin . No patient chronic systolic blood pressure ( SBP ) &lt; 90 mm Hg . If ( SBP ) &lt; 90 mm Hg day treatment intravenous fluid may administer restore intravascular volume , clinically indicate . In case , IV fluid corrects SBP study drug may give</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>fibrinolysis</keyword>
	<keyword>urokinase-type plasminogen activator</keyword>
	<keyword>plasminogen activator inhibitor</keyword>
	<keyword>aprotinin</keyword>
	<keyword>plasmin/alpha-2-antiplasmin complex</keyword>
</DOC>